Rakovina Therapeutics

📍 Vancouver, Canada🗓 Founded 2020👥 7 employees💰 Last funded Apr 2021
Biotechnology Research🌐 rakovinatherapeutics.com
Website LinkedIn
We use cutting edge Deep Docking™ AI to target DNA-damage response (DDR) mechanisms and create innovative precision medicines with the potential to improve patient outcomes across multiple tumor types. DDR is a collection of processes that identify and correct DNA damage in our cells millions of times every day. Many cancers harbor a defect in natural DDR mechanisms that allow tumor cells to evade the human immune system and grow unchecked into life-threatening malignancies. TSXV: RKV
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Canada
1
Frequently asked questions
Who invested in Rakovina Therapeutics?
Rakovina Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Rakovina Therapeutics last raise funding?
The most recent investment in Rakovina Therapeutics recorded on gritt.io was in April 2021.
When was Rakovina Therapeutics founded?
Rakovina Therapeutics was founded in 2020.
What industry is Rakovina Therapeutics in?
Rakovina Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Rakovina Therapeutics based?
Rakovina Therapeutics is headquartered in Vancouver, Canada.